38 results about "Carbocyclic nucleoside" patented technology

The present invention relates to 2′-Fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Heptatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and/or adefovir resistant) and other mutant forms of these viruses.

The present invention relates to 2′-Fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Heptatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and/or adefovir resistant) and other mutant forms of these viruses.

The invention relates to a novel nucleoside phosphate/phosphonate prodrug containing non-naturalD-amino acid ester, a preparation method and a medical purpose thereof. The novel nucleoside phosphate/phosphonate prodrug containing a substituted benzyl group is a compound shown in a formula (I) or a formula (II) or its isomer or medicinal salt, which can be used as the prodrug of various nucleoside analogues such as acyclic nucleoside, carbocyclic nucleoside, and furan ring nucleoside, biological activity of the nucleoside compound can be enhanced, so that the derivative can be used for treating virus infection and cancer.

Belonging to the field of asymmetric synthesis in organic chemistry, the invention discloses a method for synthesis of chiral five-membered carbocyclic purine nucleoside by asymmetric [3+2] cyclization reaction. The method includes: taking alpha-purine substituted acrylic ester and MBH carbonic ester as the raw materials, adopting chiral SITCP as the catalyst, and carrying out reaction to obtain achiral five-membered carbocyclic nucleoside compound. The reaction has good diastereoselectivity and enantioselectivity, and the yield is up to 93%.

The invention discloses a method for synthesizing a chiral pentabasic carbocyclic nucleoside analog by asymmetric [3+2] cycloaddition. The reaction equation is as shown in the specification. According to the method for synthesizing a chiral pentabasic carbocyclic nucleoside analog by asymmetric [3+2] cycloaddition, provided by the invention, a specific chiral catalyst is used, so that the chiral product can be obtained at a high yield and a high enantiomer excess value; besides, the reaction has the advantages that the operation is simple, the reaction condition is mild and the catalyst is inexpensive and easily obtainable, and a simple and practical synthetic method is provided for synthesis of chiral pentabasic carbocyclic nucleoside analogues.

The present invention relates to 2′-Fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Heptatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and/or adefovir resistant) and other mutant forms of these viruses, especially HBV.

The invention discloses a method for synthesizing chiral ternary carbocyclic nucleoside through asymmetric cyclopropanation triggered by Michael addition and belongs to the field of asymmetric synthesis in organic chemistry. Chiral cyclopropane carbocycle purine nucleoside is prepared from alpha-purine substituted acrylate and bromo-tert-butyl acetate as raw materials after a chiral amine catalysis reaction derived by quinine, the reaction enantioselectivity is good, and the yield is medium to excellent.

The present disclosure relates to 2′3′-cyclic dinucleotides comprising a carbocyclic nucleotide and derivatives thereof, that can modulate the activity of the STING adaptor protein.

The disclosed six-membered carbocyclic nucleoside analogues comprise: adenosine analogue, guanosine analogue, carnine analogue, mercaptopurine riboside analogue, cytidine analogue, 5-fluorocytidine analogue, uridine analogue, 5-fluorouridine analogue, and thymidine analogue as well as their acceptable salts formed by equimolar acid in pharmacy. Wherein, the opposite five-step synthesis method using the pinitol, acetone, methane sulfonyl chloride, p-toluenesulfonyl chloride, benzene sulfochloride, and nucleoside base as materials; the pyridine, water, glacial acetic acid, absolute methanol, DMSO, N, N-DMF as the solvent; the p-toluenesulfonic acid, 2, 2-dimethoxylpropane, anhydrous NaSO4, NaHCO3, triethylamine, and anhydrous K2CO3 as the catalyst. This invention restrains specially the replication of HIV and herpesvirus.

The invention discloses a method for synthesizing chiral non-cyclic and carbocyclic nucleoside analogues through asymmetric allyl ammoniation and belongs to the technical field of organic synthesis. The method comprises the steps as follows: a reaction solvent, a purine compound 1, an additive, an SKP diphosphine ligand and metal palladium are mixed, an MBH adduct 2 is added, a mixture is subjected to a thermal insulation reaction, an N-allyl olefination product 3 is obtained, and non-cyclic nucleoside 7 is obtained through DIBAL-H reduction or carbocyclic nucleoside 9 is obtained through Grubb olefin metathesis and DIBAL-H reduction in sequence. The method has the advantages of adopting available raw materials and mild reaction conditions and being simple to operate and high in selectivity, and has potential actual application value.

The invention discloses a method for synthesizing chiral three-membered purine carbocyclic nucleoside analogues through intramolecular asymmetric cycloaddition. Specifically, the N-9 intramolecular diazonium nucleoside is used as a raw material, through intramolecular asymmetry Cycloaddition Synthesis of Chiral Three-membered Purine Carbocyclic Nucleoside Analogues. In the present invention, the raw materials are easy to obtain, and the operation is simple. By using specific chiral catalysts and reaction conditions, the reaction can obtain chiral products with high yield and high enantiomeric excess value, and the reaction can be achieved in gram-level, still up to High yields and high enantiomeric excess values ​​are maintained. This reaction has several advantages such as novel and easy-to-obtain raw materials, mild reaction conditions, and cheap and easy-to-obtain catalysts. It provides a simple and practical synthetic method for the synthesis of chiral three-membered purine carbocyclic nucleoside analogues.

The present invention is directed carbocyclic nucleoside reverse transcriptase inhibitors compounds of Formula I

and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS and/or ARC.

The invention discloses a 5-formacylpyrimidine carbocyclic nucleoside and a preparation method thereof. The compound disclosed by the invention is an important intermediate for synthesizing a novel 5-substituted pyrimidine carbocyclic nucleoside medicine in a more complex structure. A 5-methylpyrimidine carbocyclic nucleoside compound, which is used as a raw material, is subjected to hydroxy protection, methyl oxidation, hydroxy protecting group removal and the like to obtain the 5-formacylpyrimidine carbocyclic nucleoside derivative. The invention has the advantages of simple and safe operational process and mild reaction conditions, and is convenient for industrial production.

Disclosed are compounds of the formula I

and the pharmaceutically acceptable salts of such compounds. Also disclosed are processes for the preparation of such compounds, intermediates used in the preparation of such compounds, and the uses of such compounds in treating inflammatory skin diseases.

The invention discloses a method for synthesizing 2'-spiro-substituted ternary carbocyclic nucleoside, and belongs to the technical field of organic chemistry. The method for synthesizing the 2'-spiro-substituted ternary carbocyclic nucleoside comprises the steps of using alpha-pyrimidine-substituted acrylate and alpha-chloronaphthenone as raw materials, and synthesizing the spiro nucleoside novelin structure through cyclopropyl cyclization reaction started by Michael reaction. According to the method for synthesizing the 2'-spiro-substituted ternary carbocyclic nucleoside, the adopted raw materials are simple and easy to obtain, in the synthesis process, and the defects of a wide variety of steps, a low yield and poor universality of a former method are overcome. The yield of the spiro pyrimidine nucleoside synthesized through the method is up to 84%, and products are rich in structure.